Abstract
Aims
The present analysis of the ARCANGELO study aims to investigate the effect of switching to different oral P2Y12 inhibitors when using cangrelor during PCIs in patients with ACS.
Methods
Out of the 995 patients meeting the criteria for this investigation, 138 transitioned to Clopidogrel (CLO), 127 to prasugrel (PRA), and 730 to Ticagrelor (TICA). Compared to the patients on PRA or TICA, users of CLO were older (median (Q1-Q3) 74(64-81) years CLO, 59(54-65) years PRA, 65(56-73) TICA; p<0.0001), had more comorbidities (37.0% CLO, 17.3% PRA, 18.9% TICA, p<0.0001), and had more frequently an NSTEMI diagnosis (68.1% CLO vs 33.1% PRA vs 35.9% TICA, p<0.0001).
Results
Five moderate bleedings were recorded without any severe episodes. There were no significant differences in the bleeding rate when switching to the different oral P2Y12 inhibitors (2.2% CLO, 5.3% TICA, 7.9% PRA, p = 0.0705) while different incidences of MACEs (4.3% CLO, 1.1% TICA, 0% PRA, p = 0.0113) and NACEs (4.3% CLO, 1.8% TICA, 0% PRA, p=0.0321) were observed during the 30 days of the study.
Conclusion
The use of cangrelor and the switch to any oral P2Y12 inhibitor in compliance with the EU SmPC is safe, with a low risk of ischemic events in routine clinical practice.
Keywords: Cangrelor, bleeding, real-world evidence, acute coronary syndrome, P2Y12 inhibitor, PCI
1. INTRODUCTION
Treatment of Coronary Artery Disease (CAD) patients with potent P2Y12 inhibitors is considered standard therapy because it significantly reduces short- and long-term ischemic events [1, 2]. The delayed onset of action of oral P2Y12 inhibitors limits their use for urgent or periprocedural treatment of patients undergoing Percutaneous Coronary Intervention (PCI) [3]. Cangrelor is the only intravenous P2Y12 inhibitor currently available. Clinical trials taking to cangrelor registration were performed when Clopidogrel (CLO) was the only oral P2Y12 inhibitor available [4-9]. These studies have consistently shown that cangrelor reduces ischemic events during PCI [7]. Limited experiences in the use of cangrelor and transition to oral P2Y12 inhibitors are available [10-12]. None of these investigated the differences in the use of the different drugs.
The itAlian pRospective Study on CANGrELOr (ARCANGELO) is a multicenter, observational, prospective cohort Post-Authorization Safety Study (PASS) designed in agreement with the guidance for category 3 [13], performed to assess the safety of cangrelor in a real-world setting and describe bleeding and Major Adverse Cardiac Events (MACEs) rates in patients undergoing PCI that require treatment with IV cangrelor switching to either Prasugrel (PRA), CLO, or Ticagrelor (TICA). The study protocol and the main results from the interim and final analyses have been presented in previous articles [14, 15]. The incidence of bleeding within 30 days post-PCI resulted below the expectations both in the interim and final analyses [14, 15], confirming the satisfactory safety profile of cangrelor when it is used according to the indications for use [16].
This article aims to report the findings of a post-hoc analysis of the ARCANGELO study to highlight variations in patient types and results when transitioning to different oral P2Y12 inhibitors while using cangrelor for PCI.
2. METHODS
The ARCANGELO study aimed to assess the safety of cangrelor in a real-world setting in Italy when administered in patients with acute coronary syndromes undergoing PCI procedures and in whom oral therapy with P2Y12 inhibitors was not feasible or desirable.
The start of the observation period was defined as the start of cangrelor administration. The observation period ended at the last visit, about 30 days after PCI. Upon the investigator’s decision to treat with cangrelor during PCI, patients willing to take part in the study were invited to sign an informed and privacy consent form for inclusion in the study. If patients could not give their informed consent before the PCI because of their medical condition, the investigator collected written informed and privacy consent from the patient after the PCI as soon as the patient’s condition permitted it and before discharge. The study was conducted in 28 Italian high-volume centers with a 24-hour available catheterism lab over 12 months. The total sample was 1004 enrolled patients. CT registration number: NCT04471870. [14].
This post-hoc analysis aimed to investigate the demographic and clinical characteristics of patients transitioning from cangrelor to oral antiplatelet transition therapy with CLO, PRA, or TICA. Patients switched to any of the oral P2Y12 inhibitors were also compared by type of intervention and incidence of Bleeding Academic Research Consortium (BARC) bleedings, MACEs, Intraprocedural Thrombotic Events (IPTE), Treatment-Emergent Adverse Events (TEAE), and Net Adverse Clinical Events (NACEs) defined as BARC 3-5 bleedings or MACE events. The timing of the administration of CLO, PRA, or TICA was also assessed.
Since the ARCANGELO study has no inferential aims, statistical tests comparing the differences between transition therapy groups were exploratory. The results of the statistical analyses were summarized by descriptive statistics, including frequency count and percentage for categorical variables, number of observations, mean ± Standard Deviation (SD) or median (Q1-Q3), and continuous variables, depending on data distribution. Statistical tests were performed on the eligible population using the Kruskal-Wallis or Analysis of Variance (ANOVA) test for continuous variables (depending on data distribution) and Bonferroni correction, when appropriate, or the Fisher exact test for categorical variables using the SAS software. Missing data were not replaced.
3. RESULTS
A total of 995 of the 1004 patients enrolled in the ARCANGELO study had data on the transition to an oral P2Y12 inhibitor and were eligible for this analysis. 138 of them were administered CLO, 127 PRA, and 730 TICA as their first oral P2Y12 inhibitor (Fig. 1). Patients with CLO were older than those with TICA and PRA: the median age was 74 (64-81) years in patients with CLO, 65 (56-73) in patients with TICA, and 59 (54-65) years in those with PRA (p<0.0001). Males were prevalent in each group, ranging from 69.6% in patients with CLO up to 81.9% in patients with PRA (p=0.0420) (Table 1).
Fig. (1).

Patient workflow by type of oral P2Y12 inhibitor used.
Table 1.
Patient's demographic and clinical history by oral P2Y12 inhibitor used.
| - | Clopidogrel (CLO) N=138 |
Prasugrel (PRA) N=127 |
Ticagrelor (TICA) N=730 |
Eligible Patients N=995 | P |
|---|---|---|---|---|---|
| Demographic Characteristics | |||||
| Age (years)§ | 74 (64-81) | 59 (54-65) | 65 (56-73) | 65 (56-73) | <0.0001 |
| Age ≥ 75 years | 65 (47.1%) | 4 (3.1%) | 146 (20.0%) | 215 (21.6%) | <0.0001 |
| Female | 42 (30.4%) | 23 (18.1%) | 159 (21.8%) | 224 (22.5%) | 0.0420 |
| Weight < 60 kg | 11 (8.0%) | 3 (2.4%) | 37 (5.1%) | 51 (5.1%) | 0.1302 |
| BMI (kg/m2)* | 27.0 (4.1) | 28.2 (4.2) | 27.5 (4.3) | 27.5 (4.3) | 0.0834 |
| Systolic BP (mmHg)* | 134.84 (25.50) | 137.20 (26.77) | 137.30 (24.48) | 136.94 (24.91) | 0.5758 |
| Diastolic BP (mmHg)* | 74.10 (14.08) | 80.98 (14.36) | 79.27 (14.10) | 78.74 (14.25) | 0.0001 |
| Heart rate (bpm)* | 73.15 (21.54) | 75.13 (16.94) | 73.67 (17.94) | 73.78 (18.36) | 0.6666 |
| Current smoker | 33 (24.8%) | 64 (51.2%) | 265 (37.6%) | 362 (37.6%) | <0.0001 |
| Clinical History | |||||
| STEMI | 44 (31.9%) | 85 (66.9%) | 468 (64.1%) | 597 (60.0%) | <0.0001 |
| NSTE-ACS | 94 (68.1%) | 42 (33.1%) | 262 (35.9%) | 398 (40.0%) | |
| NSTEMI | 47 ( 34.1%) | 34 ( 26.8%) | 191 ( 26.2%) | 272 ( 27.3%) | - |
| UA | 47 ( 34.1%) | 8 ( 6.3%) | 71 ( 9.7%) | 126 ( 12.7%) | - |
| Multi-vessel coronaropathy | 72 (52.2%) | 68 (53.5%) | 369 (50.5%) | 509 (51.2%) | 0.7950 |
| 2 vessels^ | 40 (55.6%) | 44 (64.7%) | 218 (59.1%) | 302 (59.3%) | 0.5398 |
| ≥ 3 vessels^ | 32 (44.5%) | 24 (35.3%) | 151 (40.9%) | 207 (40.7%) | |
| LAD | 98 ( 71.0%) | 89 ( 70.1%) | 510 ( 69.9%) | 697 ( 70.1%) | 0.897 |
| CX | 54 (39.1%) | 56 (44.1%) | 305 (41.8%) | 415 (41.7%) | 0.7165 |
| RCA | 78 (56.5%) | 67 (52.8%) | 376 (51.5%) | 521 (52.4%) | 0.5519 |
| LMCA | 11 (8.0%) | 6 (4.7%) | 48 (6.6%) | 65 (6.5%) | 0.6029 |
| Family history of CAD | 30 (26.8%) | 31 (26.5%) | 217 (36.1%) | 278 (33.5%) | 0.0363 |
| Prior relevant medical conditions | 51 (37.0%) | 22 (17.3%) | 138 (18.9%) | 211 (21.2%) | <0.0001 |
| Comorbidities | 132 (95.7%) | 105 (82.7%) | 591 (81.0%) | 828 (83.2%) | <0.0001 |
| Hypertension | 115 (83.3%) | 83 (65.4%) | 459 (62.9%) | 657 (66.0%) | <0.0001 |
| Hyperlipidaemia | 77 (55.8%) | 56 (44.1%) | 336 (46.0%) | 469 (47.1%) | 0.0825 |
| Diabetes mellitus | 41 (29.7%) | 22 (17.3%) | 143 (19.6%) | 206 (20.7%) | 0.0198 |
| Atrial fibrillation | 31 (22.5%) | 0 (0.0%) | 5 (0.7%) | 36 (3.6%) | <0.0001 |
| COPD | 12 (8.7%) | 4 (3.1%) | 28 (3.8%) | 44 (4.4%) | 0.0494 |
| PAD | 10 (7.2%) | 3 (2.4%) | 25 (3.4%) | 38 (3.8%) | 0.0889 |
| Chronic kidney disease | 7 (5.1%) | 1 (0.8%) | 15 (2.1%) | 23 (2.3%) | 0.0638 |
| Anaemia | 3 (2.2%) | 1 (0.8%) | 7 (1.0%) | 11 (1.1%) | 0.3581 |
| Renal failure | 2 (1.4%) | 0 (0.0%) | 5 (0.7%) | 7 (0.7%) | 0.4363 |
Note: Values are mean (SD); median (Q1-Q3); n patients (%).
Fisher exact test for dicotomic variables.
^ Percentages were calculated on eligible patients with multi-vessel as type of coronaropathy
* mean (SD); parametric ANOVA test.
§ median (Q1-Q3); Kruskal-Wallis test.
Legend: bpm=beats per minute; BMI=body mass index; BP=blood pressure; COPD= chronic obstructive pulmonary disease; CX=left circumflex artery; LMCA= left main coronary artery; NSTE-ACS=no ST-segment elevation acute coronary syndrome; NSTEMI=no ST-segment elevation myocardial Infarction; PAD= Peripheral arterial occlusive disease; RCA=right coronary artery; STEMI =ST-segment elevation myocardial infarction; UA=unstable angina.
Patients’ distribution by type of ACS was different: more than twice as many patients treated with PRA (64.1%) or TICA (66.9%) had STEMI than those treated with CLO (31.9% - p<0.0001). The percentage of patients with a family history of CAD was higher in patients with TICA (36.1%) than those with CLO (26.8%) and PRA (26.5%) (p=0.0363). The proportion of patients with prior relevant medical conditions was almost double, 37.0% in patients treated with CLO than in those using TICA (18.9%) or PRA (17.3% - p<0.0001). The rate of patients with at least an ongoing comorbidity was 95.7% in patients with CLO, 82.7% with PRA, and 81.0% with TICA (p<0.0001), having a significantly higher frequency of hypertension, diabetes mellitus, and atrial fibrillation (Table 1).
The mean duration of cangrelor infusion was 151.4 (±43.3) minutes in patients with CLO, 150.0 (±122.7) minutes in patients with TICA, and 140.2 (±34.1) minutes in those with PRA (p=0.6192).
Radial access was the most common catheter access site in each subgroup. Primary PCI duration was statistically different between CLO (52.7 ± 35.9 minutes), PRA (41.4 ± 26.2 minutes), and TICA (48.5 ± 37.3 minutes) treated patients (p=0.0363). Peri-procedural or bailout use of GPIIb/IIIa Inhibitors (GPI) was observed in each group (1.4% in patients with CLO, 2.4% in patients with PRA, and 2.9% in patients with TICA) (Table 2).
Table 2.
Procedural characteristics and concomitant antithrombotic medication use by oral P2Y12 inhibitor used.
| Clopidogrel (CLO) N= 138 |
Prasugrel (PRA) N=127 |
Ticagrelor (TICA) N=730 |
Eligible Patients N=995 |
P | |
|---|---|---|---|---|---|
| Duration of cangrelor (minutes)* | 151.4 (43.3) | 140.2 (34.1) | 150.0 (122.7) | 148.8 (106.2) | 0.6192 |
| < 2 hours | 6 (4.3%) | 6 (4.7%) | 23 (3.2%) | 35 (3.5%) | 0.6465 |
| 2-4 hours | 128 (92.8%) | 116 (91.3%) | 689 (94.4%) | 933 (93.8%) | |
| > 4 hours | 3 (2.2%) | 1 (0.8%) | 10 (1.4%) | 14 (1.4%) | |
| Radial artery access | 123 (89.1%) | 123 (96.9%) | 680 (93.2%) | 926 (93.1%) | 0.0470 |
| Duration of primary PCI (minutes)* | 52.7 (35.9) | 41.4 (26.2) | 48.5 (37.3) | 48.1 (36.0) | 0.0363 |
| Any DES | 132 (95.7%) | 126 (99.2%) | 714 (97.8%) | 972 (97.7%) | 0.1777 |
| 1 vessel with at least a DES | 111 (80.4%) | 103 (81.1%) | 585 (80.1%) | 799 (80.3%) | 0.9863 |
| 2 vessels with at least a DES | 18 (13.0%) | 20 (15.7%) | 108 (14.8%) | 146 (14.7%) | |
| 3 vessels with at least a DES | 3 (2.2%) | 3 (2.4%) | 21 (2.9%) | 27 (2.7%) | |
| Antithrombotic medication use administered in the 24 hours before or during PCI (w/wo other drugs) | |||||
| GPI peri-procedural/bailout use | 2 (1.4%) | 3 (2.4%) | 21 (2.9%) | 26 (2.6%) | 0.7215 |
| Duration of GPI (hours)§ | 16.5 (0.0-33.3) | 0.0 (0.0-0.0) | 7.7 (0-21.3) | 3.9 (0.0-21.3) | 0.2325 |
| ASA | 138 (100.0%) | 124 (97.6%) | 729 (99.9%) | 991 (99.6%) | 0.0109 |
| UFH | 122 (88.4%) | 105 (82.7%) | 621 (85.1%) | 848 (85.2%) | 0.4197 |
| LMWH | 21 (15.2%) | 5 (3.9%) | 62 (8.5%) | 88 (8.8%) | 0.0052 |
| Fondaparinux | 5 (3.6%) | 13 (10.2%) | 41 (5.6%) | 59 (5.9%) | 0.0698 |
| DOACs | 22 (15.9%) | 0 (0.0%) | 0 (0.0%) | 22 (2.2%) | <0.0001 |
| Vitamin K antagonists | 4 (2.9%) | 0 (0.0%) | 0 (0.0%) | 4 (0.4%) | 0.0006 |
Note: Values are mean (SD), median (Q1-Q3), n patients (%).
Fisher exact test for dicotomic variables.
* mean (SD); parametric ANOVA.
§ median (Q1-Q3); Kruskal-Wallis test.
Legend: ASA=acetylaalicylic acid; DES=drug-eluting stent; DOACs= oral direct factor Xa inhibitors and direct thrombin inhibitors; GPI=glycoprotein IIb/IIIa inhibitors; LMWH=low molecular weight heparin; PCI=percutaneous coronary intervention; UFH=unfractionated heparin; w/wo=with/without.
The majority of patients (563 of 900 patients for whom the time to transition was recorded) were treated with a loading dose of an oral P2Y12 inhibitor at the end of the cangrelor infusion. However, in 337 patients treated before the end of the cangrelor infusion (290 with TICA, 45 with PRA, and 2 with CLO), the loading dose of these drugs was administered at a median time of 30 minutes before stopping cangrelor (Fig. 2).
Fig. (2).

Transition to the different oral P2Y12 inhibitors - Timing and mechanisms of action.
Out of the 730 patients transferred to TICA for which data is available, 723 received the loading dose of 180 mg; 717 (98.2%) of them started the maintenance regimen of 90 mg twice daily. Out of the 138 patients treated with CLO for which data are available, 100 (72.5%) received a loading dose of 600 mg, while the other 34 patients (24.6%) received 300 mg, and 133 (96.4%) of them started the maintenance regimen of 75 mg once daily. All the patients treated with PRA for which data were available, (99.2%) received a loading dose of 60 mg followed by a maintenance dose of 10 mg once daily.
Thirty-six of the 60 patients who changed their P2Y12 during the study switched from TICA to CLO, 15 from TICA to PRA, 6 from CLO to TICA, 2 from PRA to CLO, and 1 from PRA to TICA; the main reason for using more than one oral P2Y12 inhibitor in these patients was not reported (Table 3).
Table 3.
Patients exposed to more than one oral P2Y12 inhibitor and reasons to switch.
| Clopidogrel (CLO) N= (138) | Prasugrel (PRA) N= (127) | Ticagrelor (TICA) N= (730) | Eligible Patients N= (995) | |
| Patients exposed to more than one oral P2Y12 inhibitor* | 6 (4.3%) | 3 (2.4%) | 51 (7.0%) | 60 (6.0%) |
| Reason to Switch | ||||
| New thrombotic event | 1 (0.7%) | 0 (0.0%) | 2 (0.3%) | 3 (0.3%) |
| Dyspnea | 0 (0.0%) | 0 (0.0%) | 9 (0.9%) | 9 (0.9%) |
| Physiscian's choice | 0 (0.0%) | 0 (0.0%) | 2 (0.2%) | 2 (0.2%) |
| Acute kidney failure | 0 (0.0%) | 1 (0.3%) | 0 (0.0%) | 1 (0.1%) |
| Anemia | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Atrial Fibrillation | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Bradyarthythmia and vomiting | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Optimization of cardioactive therapy | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Skin rash | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Start novel NOACs therapy | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Unknown | 5 (3.6%) | 2 (1.6%) | 32 (4.4%) | 39 (3.9%) |
Note: Values are n patients (%). * P = 0.0877.
Legend: NOACs=novel oral anticoagulants.
Cangrelor has been used off-label in 119 out of 995 patients (12.0%). The most frequent reasons included: TICA or PRA loading dose administered more than 30 minutes before cangrelor infusion end (n=74 and n=4, respectively); TICA loading dose administered before the start of cangrelor infusion (n=16) and cangrelor duration < 2 hours (n=12).
No safety issues were observed in the cases where off-label timing use to transition to TICA or PRA was observed.
In the 48 hours (± 24 hours) following the PCI, the incidence of BARC type 1-2 (mild) bleeding ranged from 1.4% (n=2) in patients with CLO to 6.3% (n=8) in those with PRA (p = 0.0705), while BARC type 3-5 (moderate-severe) bleedings were observed only in 3 (0.4%) patients treated with TICA (p = 1.0000). During the 30 days of the study, the incidence of BARC type 1-2 bleeding ranged from 2.2% (n=3) in patients with CLO to 7.9% (n=10) in those with PRA (p = 0.0994), while BARC type 3-5 (moderate-severe) bleedings were observed in 5 of the patients with TICA (0.7%) (p = 1.0000) (Fig. 3).
Fig. (3).

Percentage of patients with bleeding by oral P2Y12 inhibitor. Legend: BARC 1-2: Bleeding Academic Research Consortium grade 1-2 bleeding; BARC 3-5: Bleeding Academic Research Consortium grade 3-5 bleeding.
The 3 (0.4%) of the 52 patients experiencing at least one bleeding within the 30 days post-PCI correlated, among other factors, to cangrelor were using TICA. A total of 7 patients experienced a bleeding event requiring transfusion within the 30 days post-PCI: 6 (0.8%) treated with TICA and 1 (0.8%) with PRA (p = 0.6893).
Three (2.2%) patients treated with CLO and 7 (1.0%) with TICA (p = 0.1827) experienced at least one MACE within 48 hours (±24 hours) post-PCI (p = 0.1827); the corresponding incidences at 30 days were 4.3% (n=6) in patients with CLO and 1.1% (n=8) in those with TICA; no MACEs were observed in patients with PRA during the study (n=127) (p = 0.0113). Three of the patients treated with CLO (2.2%) and 3 of those treated with TICA (0.4%) died, while 1 patient treated with CLO (0.7%) and 1 treated with TICA (0.1%) experienced an ST (Table 4).
Table 4.
Incidence of major adverse cardiac events (MACEs) within 48 (±24) hours and 30 (±3) days post-PCI.
| - | Clopidogrel (CLO) N=138 | Prasugrel (PRA) N=127 | Ticagrelor (TICA) N=730 | Eligible Patients N=995 |
|---|---|---|---|---|
| Patients experiencing at least one MACE 48 hours* | 3 (2.2%) | 0 (0.0%) | 7 (1.0%) | 10 (1.0%) |
| All-cause death | 1 (0.7%) | 0 (0.0%) | 3 (0.4%) | 4 (0.4%) |
| At least one MI (all types) | 2 (1.4%) | 0 (0.0%) | 3 (0.4%) | 5 (0.5%) |
| Type 1 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Type 2 | 1 (0.7%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
| Type 4a | 1 (0.7%) | 0 (0.0%) | 3 (0.4%) | 4 (0.4%) |
| Type 4b | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| At least one IDR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| At least one ST (all types) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Patients experiencing at least one MACE 30 days# | 6 (4.3%) | 0 (0.0%) | 8 (1.1%) | 14 (1.4%) |
| All-cause death | 3 (2.2%) | 0 (0.0%) | 3 (0.4%) | 6 (0.6%) |
| At least one MI (all types) | 3 (2.2%) | 0 (0.0%) | 4 (0.5%) | 7 (0.7%) |
| Type 1 | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) | 1 (0.1%) |
| Type 2 | 2 (1.4%) | 0 (0.0%) | 0 (0.0%) | 2 (0.2%) |
| Type 4a | 1 (0.7%) | 0 (0.0%) | 3 (0.4%) | 4 (0.4%) |
| Type 4b | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| At least one IDR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| At least one ST (all types) | 1 (0.7%) | 0 (0.0%) | 1 (0.1%) | 2 (0.2%) |
Note: Values are n patients (%). *p=0.1827; # p = 0.0113 Fisher exact test. Legend: MACE = major adverse cardiac events; IDR = ischemia-driven revascularization; MI = myocardial infarction; PCI = percutaneous coronary intervention; ST = stent thrombosis.
The incidence of IPTE within 48 hours post-PCI ranged from 1.2% (n=9) in patients treated with TICA (0.5% no-reflow and 0.3% slow re-flow) to 2.2% (n=3) with CLO. Patients experiencing at least one NACE during the observation period were 13 (1.8%) of those treated with TICA and 6 (4.3%) with CLO; no NACEs were observed in patients with PRA (p=0.0321).
A total of 30 (21.7%) patients treated with CLO, 28 (22%) with PRA, and 168 (23%) with TICA (p = 0.9533) experienced at least one TEAE during the observation period; the corresponding incidence of serious TEAEs were 13 (9.4%) for CLO, 4 (3.1%) for PRA and 36 (4.9%) for TICA (p = 0.0619). TEAEs related to cangrelor were observed in 6 (0.8%) patients treated with TICA (p = 0.6598).
4. DISCUSSION
The ARCANGELO study was designed according to stringent requirements of the regulatory authorities and was conducted to evaluate the transition to all P2Y12 inhibitors after using cangrelor during PCI. Each patient had to be treated following the most appropriate clinical practice, as per the Investigator’s judgment [14, 15]. This subanalysis evaluated how Italian interventional cardiologists approach the transition from cangrelor to other oral P2Y12 inhibitors.
Confirming the outcomes from other observational trials [17], ticagrelor was the oral P2Y12 inhibitor more frequently used in PCI-treated patients after cangrelor infusion. Patients who were older and had more comorbidities—such as chronic kidney disease and a history of anemia—that could increase their risk of bleeding were more frequently switched to clopidogrel [18]. Furthermore, for patients with atrial fibrillation requiring treatment with low molecular weight heparin, vitamin K antagonist, or DOACs (oral direct factor Xa inhibitors and direct thrombin inhibitors), including [19] Dual Antiplatelet Therapy (DAPT) with aspirin plus clopidogrel, was the treatment of choice. These observations confirm that the Italian investigators participating in the ARCANGELO study are perfectly in line with the current recommendations on the use of DAPT, especially in patients with high bleeding risk [20, 21]. Furthermore, these results provide a snapshot of the real-world approach of the Italian interventional cardiologists in the transition from cangrelor to oral P2Y12 inhibitors because more potent P2Y12 inhibitors were widely used, and clopidogrel was preferred for transition in patients for whom the perception of an increased bleeding risk was higher. The correctness of this type of approach is demonstrated by the data on bleeding in the present study, since the incidence of bleeding was 2.2% with clopidogrel, 5.3% with ticagrelor, and 7.9% with prasugrel, even if clopidogrel was most frequently used in the older patients included in the ARCANGELO study [22]. Interestingly, the rate of bleeding events observed in the present report is significantly lower than that observed in the studies belonging to the CHAMPION program (16.8%). In those studies, clopidogrel was the P2Y12 inhibitor of choice for transition [5, 6, 7, 9, 23]. Thus, it might be speculated that, in our real-world experience, however, more potent P2Y12 inhibitors were widely administered for transition after cangrelor infusion during PCI. A more accurate clinical evaluation of the bleeding risk might have driven a more appropriate antiplatelet therapy to reduce the incidence of bleeding events. Two other real-world registries by the same research group have recently evaluated bleeding after the transition to P2Y12 inhibitors other than clopidogrel in cangrelor-treated patients. However, one of them was focused on patients with cardiogenic shock as a clinical presentation only. Moreover, since both studies were published as research letters, they enrolled a small number of patients. They imported a limited number of mild to moderate bleeding events without explaining the actual rate of these events according to the P2Y12 inhibitor used, as we do in the present report [24, 25].
Another possible explanation for the lower rate of bleeding observed as compared to the CHAMPION trials is that interventional cardiologists preferred radial access to perform coronary revascularization in our study, while femoral access was widely used in those trials [26]. One of the aspects of bleeding avoidance strategies in PCI includes a selection of vascular access, as well as antithrombotic treatment regimens [27]. We might speculate that both these aspects have significantly improved in PCI management in recent times, finally contributing to the reduced bleeding complications observed.
Transition to oral P2Y12 inhibitors has been recently investigated in the CAMEO Registry, [17] indicating a significant interhospital variability in cangrelor dosing and administration of oral P2Y12 inhibitors. Specifically, in that study, only a quarter of patients were treated consistently with trial‐established, FDA‐approved recommendations. Interestingly, MACEs occurred in 10.3% of patients not treated according to the established treatment strategy compared to 6.3% of the same events observed in patients treated according to the established treatment strategy. This study's overall rate of MACEs was significantly lower than that of the CAMEO. Moreover, we have observed, for the first time, the rate of MACEs in patients who were treated in line to cangrelor SmPC indications for transition accordingly to the different P2Y12 inhibitors: clopidogrel (4.3%), prasugrel (0%), and ticagrelor (0.1%). A possible explanation for these different results might be that, in the CAMEO registry, a longer time gap occurred between cangrelor discontinuation and P2Y12 inhibitor administration, thus permitting a vulnerable period of “interruption” in antiplatelet therapy. About 50% of patients who transitioned to clopidogrel had a >1‐hour gap, while this occurred less frequently with prasugrel and with ticagrelor. This time gap was not observed in our study since the transition timing was done according to SmPC indications.
As with other post-hoc analyses, these observational ARCANGELO study results must be interpreted cautiously. Even if we have used the Bonferroni correction when comparing multiple groups to mitigate the risk of Type I errors, the findings from this post-hoc analysis should be considered exploratory and need to be validated with further research. Furthermore, the presented analyses were performed without any adjustment or inclusion of any covariate because of the low frequency of the examined events in each of the samples; thus, all the presented comparisons have only an indicative, non-inferential value. Additionally, because of the few events (bleedings, MACEs, NACEs) observed in the study, any model to identify their predicting factors was not applicable from a statistical standpoint.
CONCLUSION
This post-hoc analysis of a real-world study confirms that cangrelor is safe. Moreover, these data suggest that the transition from cangrelor to oral P2Y12 inhibitors can be safely performed, with an accurate clinical evaluation of the patient ischemic and bleeding risk. Timing of the transition might play a pivotal role in reducing the risk of potential ischemic risk due to partial interruption of antiplatelet therapy. Although randomized studies should be performed to have a clearer point of view on this important topic of antithrombotic therapy, these results might be helpful in daily practices in indicating how to perform the transition from cangrelor to the different oral P2Y12 inhibitors.
LIST OF ABBREVIATIONS
- BARC
Bleeding academic research consortium
- CAD
Coronary artery disease
- CLO
Clopidogrel
- IPTE
Intraprocedural thrombotic events
- MACEs
Major adverse cardiac events
- NACEs
Net adverse clinical events
- PCI
Percutaneous coronary intervention
- PRA
Prasugrel
- TEAE
Treatment-emergent adverse events
- TICA
Ticagrelor
AUTHORS' CONTRIBUTIONS
The authors confirm their contribution to the paper as follows: study conception and design: L.D.L, P.C., F.V., F.T., M.P., S.B., C.C., G.M.; data collection: P.C., E.N., C.M., C.T., A.M. All authors reviewed the results and approved the final version of the manuscript.
CONSENT FOR PUBLICATION
Informed consent was obtained from all participants.
STANDARDS OF REPORTING
CONSORT guidelines were followed.
AVAILABILITY OF DATA AND MATERIALS
The data and supportive information are available within the article.
FUNDING
The study was fully sponsored by Chiesi Italia S.p.A.
CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
ACKNOWLEDGEMENTS
Medineos was responsible for project and site management, data management, quality control, and statistical analysis. The authors thank Andrea Rossi, who provided medical writing support for the article's preparation, Eustacchio Montemurno for graphic support, and the Chiesi study team (Enrica Baraldi, Eleonora Ingrassia, Stella Fiorini, Giovanni Piotti) for the study's management. Chiesi funded all the activities.
The authors thank the patients, their relatives, and the personnel of the centers involved in the Arcangelo study group, who performed the clinical procedures and collected the data for this study. The participating centers are listed below:
UOC Cardiologia Clinica con UTIC, A.O.R.N. Sant'Anna e San Sebastiano, Caserta.
UOC Cardiologia, Ospedale San Bassiano, Bassano del Grappa (VI).
S.C. Cardiologia, Ospedale degli Infermi di Rivoli, ASL TO.
S.C. Cardiologia, Ospedale S. Andrea, La Spezia, ASL5 Liguria.
U.O. Cardiologia, A.O.U. Policlinico G. Rodolico, Catania.
Cardiologia, Ospedale Fabrizio Spaziani, Frosinone.
UO Cardiologia Interventistica, Strutturale e Pediatrica, Ospedali Riuniti, Ancona.
Cardiologia UTIC con Emodinamica, AORN Cardarelli, Napoli.
UOC Interventistica Cardiologica e Diagnostica Invasiva, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma.
Department of Cardiology, Santa Maria Goretti Hospital, Latina.
UOC di Cardiologia, Aurelia Hospital.
SC Cardiologia, AO Ordine Mauriziano, Torino.
Cardiologia UTIC, Ospedale San Camillo Forlanini, Roma.
Interventistica Cardiologica Strutturale, A.O.U. Careggi, Firenze.
Cardiologia Universitaria, A.O.U. Consorziale Policlinico.
Fondazione C.N.R. Regione Toscana G. Monasterio, Pisa
Cardiologia, Ospedale Ca' Foncello, Treviso.
Dipartimento di Scienze Biomediche Avanzate, Cardiologia, AOUP “Federico II”, Napoli.
Cardiologia Emodinamica, Fondazione Poliambulanza, Brescia.
UOC Cardiologia Clinica ed Interventistica, Ospedale SS. Annunziata, Sassari.
UOC Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
UOC di Cardiologia con UTIC ed Emodinamica, Ospedale Umberto I di Siracusa, Azienda Sanitaria Provinciale di Siracusa.
UOC Cardiologia, Ospedale Maggiore, Bologna.
UOC Cardiologia Interventistica e UTIC, Azienda Ospedaliera San Pio, Benevento.
UOSD Emodinamica e Cardiologia Interventistica, Azienda Ospedale Università Padova.
UO Cardiologia, Ospedale S. Chiara, Trento.
Cardiologia, ASO Santa Croce e Carle, Cuneo.
Cardiologia, Ospedale San Donato, Arezzo.
REFERENCES
- 1.Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516. doi: 10.1016/j.jacc.2006.11.044. [DOI] [PubMed] [Google Scholar]
- 2.De Luca L., Leonardi S., Cavallini C., et al. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT study. Eur Heart J Acute Cardiovasc Care. 2015;4(5):441–52. doi: 10.1177/2048872614560505. [DOI] [PubMed] [Google Scholar]
- 3.DL Bhatt, GW Stone, KW Mahaffey, CM Gibson. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–1313. doi: 10.1056/NEJMoa1300815. [DOI] [PubMed] [Google Scholar]
- 4.Franchi F., Rollini F., Muñiz-Lozano A., Rae Cho J., Angiolillo D.J. Cangrelor: A review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11(10):1279–91. doi: 10.1586/14779072.2013.837701. [DOI] [PubMed] [Google Scholar]
- 5.Cavender M., Harrington R., Stone G., et al. Early benefit of cangrelor in patients undergoing pci in champion phoenix. Eur Heart J. 2014;35(35):P732. [Google Scholar]
- 6.Jatene T., Harrington R.A., Stone G.W., Steg P.G., Gibson C.M., Hamm C.W. Investigator-reported bleeding versus post Hoc adjudication of bleeding: Lessons From the champion phoenix trial. J Am Coll Cardiol. 2016;67(5):598. doi: 10.1016/j.jacc.2015.11.027. [DOI] [PubMed] [Google Scholar]
- 7.White H.D., Chew D.P., Dauerman H.L., et al. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the champion trials using the universal definition of myocardial infarction. Am Heart J. 2012;163(2):182–190.e4. doi: 10.1016/j.ahj.2011.11.001. [DOI] [PubMed] [Google Scholar]
- 8.Abtan J., Steg P.G., Stone G.W., et al. Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;9(18):1905–1913. doi: 10.1016/j.jcin.2016.06.046. [DOI] [PubMed] [Google Scholar]
- 9.White H.D., Bhatt D.L., Gibson C.M., et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights from the champion phoenix (A clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI]). JACC Cardiovasc Interv. 2015;8(3):424–33. doi: 10.1016/j.jcin.2014.09.025. [DOI] [PubMed] [Google Scholar]
- 10.Mohammad M.A., Andell P., Koul S., et al. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets. 2017;28(4):414–6. doi: 10.1080/09537104.2016.1246714. [DOI] [PubMed] [Google Scholar]
- 11.Badreldin H.A., Carter D., Cook B.M., Qamar A., Vaduganathan M., Bhatt D.L. Safety and tolerability of transitioning from cangrelor to ticagrelor in patients who underwent percutaneous coronary intervention. Am J Cardiol. 2017;120(3):359–61. doi: 10.1016/j.amjcard.2017.04.034. [DOI] [PubMed] [Google Scholar]
- 12.Linfante I., Ravipati K., Starosciak A.K., Reyes D., Dabus G. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. J Neurointerv Surg. 2021;13(1):30–2. doi: 10.1136/neurintsurg-2020-015841. [DOI] [PubMed] [Google Scholar]
- 13.Post-authorisation safety studies (PASS). 2022. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/post-authorisation-safety-studies-pass-0.
- 14.De Luca L., Calabrò P., Chirillo F., et al. Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clin Cardiol. 2022;45(9):913–20. doi: 10.1002/clc.23878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.De Luca L., Calabrò P., Capranzano P., et al. Safety of cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: The ARCANGELO study. Eur Heart J Open. 2023;3(4):oead076. doi: 10.1093/ehjopen/oead076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Annex I : Summary of product characteristics. 2021. Available from: https://ec.europa.eu/health/documents/community-register/2021/20210223151110/anx_151110_en.pdf.
- 17.Rymer J.A., Bhatt D.L., Angiolillo D.J., et al. Cangrelor use patterns and transition to oral P2Y12 inhibitors among patients with myocardial infarction: initial results from the CAMEO registry. J Am Heart Assoc. 2022;11(11):e024513. doi: 10.1161/JAHA.121.024513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Urban Defining high bleeding risk in PCI patients. 2019. Available from: http://ahajournals.org.
- 19.Hindricks G., Potpara T., Dagres N., et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS). Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612. [DOI] [PubMed] [Google Scholar]
- 20.Lawton J.S., Tamis-Holland J.E., Bangalore S., et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: Executive summary. J Am Coll Cardiol. 2022;79(2):197–215. doi: 10.1016/j.jacc.2021.09.005. [DOI] [PubMed] [Google Scholar]
- 21.Patti G., Micieli G., Cimminiello C., Bolognese L. The role of clopidogrel in 2020: A reappraisal. Cardiovasc Ther. 2020 doi: 10.1155/2020/8703627. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Capranzano P., Calabrò P., Musumeci G., et al. Use of cangrelor in older patients: Findings from the italian prospective study on cangrelor study. Am J Cardiol. 2025;240:31–7. doi: 10.1016/j.amjcard.2024.12.021. [DOI] [PubMed] [Google Scholar]
- 23.Cavender M.A., Bhatt D.L., Stone G.W., et al. Consistent reduction in periprocedural myocardial infarction with cangrelor as assessed by multiple definitions. Circulation. 2016;134(10):723–33. doi: 10.1161/CIRCULATIONAHA.115.020829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Vaduganathan M., Qamar A., Badreldin H.A., Faxon D.P., Bhatt D.L. Cangrelor use in cardiogenic shock: A single-center real-world experience. JACC Cardiovasc Interv. 2017;10(16):1712–4. doi: 10.1016/j.jcin.2017.07.009. [DOI] [PubMed] [Google Scholar]
- 25.Vaduganathan M., Qamar A., Singh A., Venkateswaran R.V., Szumita P.M., Croce K.J. Cangrelor use since FDA approval: A single-center, real-world experience at a tertiary care hospital. J Am Coll Cardiol. 2017;69(4):463–464. doi: 10.1016/j.jacc.2016.11.017. [DOI] [PubMed] [Google Scholar]
- 26.Cavender M., Harrington R., Stone G., et al. Ischemic events occur early in patients undergoing pci and are reduced with cangrelor: Findings from champion phoenix. J Am Coll Cardiol. 2017;69(11):25. doi: 10.1016/S0735-1097(17)33414-9. [DOI] [Google Scholar]
- 27.Capodanno D., Bhatt D.L., Gibson C.M., et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022;19(2):117–32. doi: 10.1038/s41569-021-00598-1. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data and supportive information are available within the article.
